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Influenza vaccination and AMI/stroke 
Pneumococcal vaccination and AMI 
• Case control study 
• Pneumococcal vaccination was associated with a 
decrease of more than 50% in the rate 
myocardial infarction 2 years after exposure. 
Lamontagne et al. CMAJ 2008:179: 773-777 
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Previous studies 
• Contradictory evidence 
• Bias: recall, therapeutic 





To investigate association of influenza & 
pneumococcal vaccination for AMI or stroke 
using GPRD/CPRD and using 
a. Matched case-control design 




• Matched case-control design  
• AMI:  1/11/2001 – 31/05/2007  
• Stroke:  1/9/2001 –  31/8/2009 
• Outcome: first AMI or stroke (fatal or non-fatal) 
• Exposure 
– prior influenza vaccination (≤ 1 year, within season) 
– prior pneumococcal vaccination (ever) 
– combined vaccination  
• Inclusion: 
– ≥ 40+ years at incident diagnosis 
– ≥ 5 years of complete follow-up data 
– alive from beginning of study to index date  




• ‘Case:  Read/OXMIS codes of first AMI 
• ‘Index date’: first date when GP recorded 
AMI/stroke code (fatal/non-fatal) in 
clinical/referral record 
• ‘Control’: 4 (AMI) or 1(stroke) age/sex matched 
controls per case with index date corresponding 
to date of matched case 
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Analysis: case-control 
• STATA: conditional logistic regression 
• Outcomes: adjusted odds ratios 
• Confounding factors considered for adjusted OR 
– Vaccine risk groups: chronic heart (and other 
cardiovascular diseases); diabetes, asthma/COPD; 
chronic renal and liver disease; splenectomy 
– Other CHD risk factors: smoking status; 
hyperlipidaemia; BMI; family history of AMI; 
antihypertensive treatment, recent aspirin or statin 
therapy 
– Frequency of GP visits (frailty/disability) 
– [Comorbidities] 
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Age (years):      Mean (SD) 
  95% CI 
70.4 (12.7) 
70.2 – 70.6 
70.0 (12.5) 
69.9 – 70.1 
70.1 (12.6) 
70.0 – 70.2 
Aged over 65  
years (%) 







Gender:             Male (%) 
    
61.5 61.5 61.5 
 
Index period: Dec – Feb 
   Mar – May       
  (%) Jun – Aug 










Descriptive statistics: stroke 
Cases (those with 
stroke/TIA) 
N= 47,216 (%) 
 
Controls 
N= 47,216 (%) 
 
Age (years):          Mean (SD) 
             95% CI 
79.8 (13.4) 
79.7 – 80.0 
79.8 (13.4) 
79.7 – 80.0 
Aged over 65 years  76.8 76.8 
Gender:                 Male 48.0 48.0 
Index period:    Sep – Nov  
                         Dec – Mar  
                          April – Aug 






Vaccine risk groups Case 






Asthma or COPD 
 
  1980 (12.4)   5803 (9.3) <0.001 
Chronic heart disease 
 
  3756 (23.5)   6174 (9.9) <0.001 
Other vascular diseases 
  
  1280 (8.0)   2956 (4.7)  <0.001 
Diabetes 
 
  2451 (15.3)   5637 (9.0)  <0.001 
Splenectomy 
 
       36 (0.2)      116 (0.2)  0.306 
Chronic liver disease 
 
       30 (0.2)        93 (0.2)  0.265 
Chronic renal disease       584 (3.7)      724 (1.2)  <0.001 
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Hyperlipidaemia 13.6 9.3 <0.001 
Smoking history   
   Never smoked 
  Ex-smoker 











Body mass index ≥ 25 63.2 59.5 <0.001 
Family history of MI 1.9 1.5 0.001 
Aspirin 0.4 0.2 <0.001 
Statin 11.4 7.0 <0.001 
Antihypertensive treatment 6.5 3.9 <0.001 
+GP consultations in last 5 















OR 95% CI 






























OR 95% CI 
 
Same season as 










0.77 – 0.85 
Early within-














0.97 0.88 – 1.06 
Main results: stroke case-control 
Main results: pneumococcal vaccine  
• AMI - Pneumococcal: adjusted OR 0.96 95% CI 0.91 
to 1.02  
• Stroke - Pneumococcal: adjusted OR 0.97 95% CI 
0.92 to 1.02  
• Combined influenza and pneumococcal vaccination 
was no better than influenza vaccination alone  
 
 
Study strengths and limitations 
• Residual confounding (unknown factors) 
• ‘Healthy vaccination’ bias 
• Incomplete recording of blood pressure, 
cholesterol levels, height, etc. on the GPRD 
Observation period 2001-2007 (AMI)/2001-2009 (stroke)  
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Method: self controlled case series 









14 days post-vaccination  
15 -28  days post-vaccination  
29 - 59  days post-vaccination  
60 -90  days post-vaccination  
91-120  days post-vaccination  
121-180  days post-vaccination  
14 days pre-vaccination  




• 1-14 days pre-vaccination  considered as a separate 
interval: a stroke/TIA event occurring during this 
period is likely to affect the subsequent likelihood of 
receiving an influenza vaccination.  
•  Seasonality was included by dividing the risk periods 
into one of four quarterly seasons: Sept. to Nov., Dec. 
to Feb., March to May and June to Aug. 
 
Method: self controlled case series 
 • The incidence rate of AMI/stroke in exposure periods 
after vaccination compared with the incidence rate 
during a baseline period.  
• Statistical modelling with conditional Poisson 
regression in Stata 12 was employed to compute 




Analysis: self controlled case series 
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• First cases of AMI (14k) or stroke/TIA (40k) within the 
observation period 
• Excluded cases that either did not receive influenza 
vaccination or have a AMI/stroke diagnosis on or 






• 8 180 of AMI considered for the final analysis.  
• 38 674 cases of stroke/TIA  considered for the final 
analysis.  
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Risk period Number of cases Time at risk (person years) IRR 
Adjusted 
95% CI 
  N %       
Baseline period 3913 47∙8 16898 1∙00 - 
Post Vac 1-14 days 
275 3∙4 1413 0∙68 (0∙60 - 0∙78) 
15-28 days 
289 3∙5 1410 0∙75 (0∙66- 0∙86) 
29-59 days 
703 8∙6 3106 0∙82 (0∙75 - 0∙90) 
60-90 days 
826 10.1 3073 0∙96 (0∙87 - 1∙07) 
91-120 days 
762 9∙3 2926 0∙98 (0∙89 - 1∙09) 
121-180 days 
1273 15∙6 5290 1∙02 (0∙95 – 1∙10) 
 a Adjusted for seasonality 
b IRR incidence rate ratios. 
c Baseline is between 180 days or 30th of April (whichever came first) after vaccination and 14 days prior to next vaccination 
 
Main results: AMI and flu vaccination 
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Risk period Number of cases Time at risk (person years) IRR 
Adjusted 
95% CI 
  N %       
Baseline period 
24,333 62∙9 173926 1∙00 - 
Post vac 1-14 days 
1,084 2∙8 8270 0∙88 (0∙82 - 0∙94) 
15-28 days 
1,040 2∙7 7695 0∙91 (0∙85 - 0∙97) 
29-59 days 
2,184 5∙7 16776 0∙86 (0∙82 - 0∙90) 
60-90 days 
2,444 6∙3 17324 0∙92 (0∙87 - 0∙96) 
91-120 days 
2,315 6∙0 16194 0∙94 (0∙89 - 0∙98) 
121-180 days 
4,332 11∙2 30525 0∙96 (0∙93 – 1∙00) 
 a Adjusted for seasonality 
b IRR incidence rate ratios. 
c Baseline is between 180 days or 30th of April (whichever came first) after vaccination and 14 days prior to next vaccination 
 
Main results: stroke and flu vaccination 
Conclusion 
• Large, representative and robust research database 
with sufficient power to detect effects with 
precision. 
• Selection bias minimized by including all cases of 
AMI or stroke within the selected time period. 
• Method accounts for unknown and known 




Study strengths and limitations 
Conclusions 
• Influenza vaccination associated with reduced 
risk of AMI and stroke 
• Early influenza seasonal vaccination (September 
to mid-November) associated with lower rate of 
AMI or stroke than later vaccination (mid-
November to January) 
• Pneumococcal vaccination not associated with a 
reduction in rate of AMI or stroke 
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Implications for practice 
• Reinforce recommendations: + younger people 
(40-64) at risk 




Implications for future research 
• Mechanism:?Virchov’s triad 
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